Dialysis industry news

Stories from the dialysis comunity across the globe.



Blacks at Higher Risk of Sudden Cardiac Arrest - Renal and Urology News PDF Print
July 23, 2015 Blacks at Higher Risk of Sudden Cardiac Arrest - Renal and Urology News
Higher rates of sudden cardiac arrest are seen in blacks versus whites and often at younger ages.

(HealthDay News) -- Blacks are more likely than whites to experience sudden cardiac arrest and it often occurs at an earlier age in blacks than in whites, according to research published online in Circulation.

Sumeet Chugh, M.D., associate director of the Cedars-Sinai Heart Institute in Los Angeles, and colleagues collected data on 1,262 whites and 126 blacks. They all had experienced sudden cardiac arrest between 2002 and 2012. While 33% of the whites in the study had diabetes, 52% of the blacks did. Hypertension was an issue for 77% of the blacks, compared to 65% of the whites. Chronic renal insufficiency was nearly twice as likely in blacks, with 34% of them having the condition, the researchers found.

Blacks in the United States tend to have sudden cardiac arrest an average of 6 years earlier than whites, Chugh told HealthDay. In his study, he found other major differences as well. "Blacks, in addition to being younger, tended to have more diabetes, more high blood pressure, and more kidney problems, or chronic renal disease," he said.

Chugh added that he isn't certain what's driving the differences in sudden cardiac arrest between blacks and whites. It's possible it might be genetics, cultural differences in lifestyle or other factors, he suggested. Inadequate health coverage may be another factor.

Source

  1. Reinier, K; Nichols, GA; Huertas-Vazquez, A; et al. Circulation, published online before print July 20, 2015; doi: 10.1161/CIRCULATIONAHA.115.015673.

...

 
Medical practice to revive vacant college | Richmond BizSense - RichmondBizSense PDF Print
Medical practice to revive vacant college | Richmond BizSense - RichmondBizSense

The former Centura College building is being converted into a new medical space. Photo by Katie Demeria.

A local medical practice is breathing new life into a vacant 48-year-old Broad Street building.

Richmond Nephrology Associates, a local practice of kidney specialists with five locations, is renovating the 25,000-square-foot Centura College building at 7001 W. Broad St. into a new medical office.

The practice purchased the two-story building at the end of March for $1.9 million. Dr. Ari Hirsch of Richmond Nephrology Associates said the group will relocate its West End office to the new space.

“We’re transforming the building into what we believe will be a center for excellence of kidney care for Richmond’s north side,” Hirsch said. “I think the county will like that we’re going to be taking one of the ugliest properties on Broad Street and redeveloping it so it looks really nice.”

Richmond Nephrology Associates will take up 5,000 square feet in the building’s second floor, Hirsch said. Another tenant will fill out the rest of the leasable space with close to 13,000 square feet, including the entire first floor and a portion of the second. Hirsch declined to name the second tenant.

Richmond Nephrology Associate’s new office will open in December.

Work is currently underway to gut the building and vastly improve the exterior, Hirsch said. He declined to share the renovation costs.

“For our practice, it’s very exciting to grow and contribute back to the city, the county and our patients,” he said. “Honestly, nobody wants to see a kidney doctor, so offering them a place that’s comfortable, warm and inviting is important to us.”

ECI Development is overseeing the project, Bowman Consulting is providing engineering services, Emerald Construction is the general contractor and Baskervill Architects designed it.

The building has been vacant for more than a year, after Centura College moved out in 2013. Brandywine Realty Trust had handled the listing until Colliers International took it over.

Tyler Miller and Bill Mattox of Colliers represented the seller, Emily Walker, who had owned the building since 1993. Susan Jones, also of Colliers, represented Richmond Nephrology Associates.

Miller said Colliers took over the listing last year. It went under contract within a week, then took about six months to close.

“We had instant interest,” Miller said. “It was a good deal for everyone involved.”

About 12 employees will be relocated to Richmond Nephrology Associates’ new office.

The practice was founded about 25 years ago and has other offices in Midlothian, on the Southside on Hioaks Road, in Chesterfield County’s Watkins Center, and in Amelia County.

The Centura College building will join a few other medical office buildings rising throughout Henrico County. Local pharmacist Chris Currin is working on the development of a two-story medical office building in Towne Center West, and the first of three buildings in the West Creek Medical Park was recently completed.

...

 
Dialysis units recalled for second time in American Samoa - Radio New Zealand PDF Print
LBJ hospital, American Samoa

LBJ hospital, American Samoa

Photo: RNZI

Dialysis treatment at American Samoa's hospital has been suspended again, after another chemical recall.

There was a three-day closure in June when the manufacturer of bicarbonate solution, announced a recall of all supplies at the hospital.

The CEO of LBJ Hospital, Taufete'e John Faimuina, says the company has recalled the units again.

He is now seeking permission from the Governor, Lolo Moliga, to search all incoming shipping containers for units that don't feature the recalled lot numbers.

If unsuccessful, the hospital management is aiming to air freight emergency supplies on Wednesday's Hawai'ian Air flight.

In the meantime patients are being told to be calm, and stick to their diet plans while their dialysis sessions have been cancelled.

Related

...

 
Dialysis units recalled for second time in American Samoa | Radio New Zealand News - Radio New Zealand PDF Print

Radio New Zealand

Dialysis units recalled for second time in American Samoa | Radio New Zealand News
Radio New Zealand
Dialysis treatment at American Samoa's hospital has been suspended again, after another chemical recall. There was a three-day closure in June when the manufacturer of bicarbonate solution, announced a recall of all supplies at the hospital. The CEO of ...

...

 
Immunotherapy Combinations in Renal Cell Carcinoma - OncLive PDF Print

Immune checkpoint inhibitors have shown clinical activity in patients with advanced renal cell carcinoma (RCC). The distinct mechanism of action of these therapies represents the potential for combination strategies, suggests Thomas Hutson, DO, PharmD. In early studies assessing the combination of VEGF inhibitors with anti–PD-1 or –PD-L1 antibodies, adverse events (AE) were a challenge, particularly hepatotoxicity, although promising activity was also observed, Hutson notes. 

The AE profile with immune checkpoint inhibition is different than experienced with therapies against VEGF and mTOR, Hutson notes. Immune checkpoint inhibition causes the activation of T-cells against normal host cells along with tumor cells. This activation can cause flu-like symptoms, along with damage to the skin, gastrointestinal tract, adrenal glands, and pituitary gland.

As a single-agent, the PD-1 inhibitor nivolumab demonstrated activity in patients with metastatic clear-cell RCC. At a 2.0 mg/kg dose, the treatment showed a progression-free survival of 4 months, an objective response rate of 22%, and a median overall survival (OS) of 25.5 months in patients with previously treated mRCC. Interestingly, since these therapies are immune-based, histology should not significantly impact efficacy, suggesting that there should be activity in both clear cell and non-clear cell histologies, Hutson notes.
 
Top-line findings from the pivotal phase III CheckMate-025 study revealed that second-line nivolumab improved OS compared with everolimus for patients with metastatic RCC, although full data were not yet released. Results from this study are eagerly anticipated, particularly since profound and prolonged responses have been observed in a subset of patients, Eric Jonasch, MD comments. There are very limited data in untreated patients, which is the setting that is ideal for immunotherapy, notes David F. McDermott, MD.
 

In untreated patients with RCC, a number of trials are assessing combination strategies. In the phase III CheckMate-214 trial, nivolumab is being explored in combination with the CTLA-4 inhibitor ipilimumab in comparison with sunitinib (NCT02231749). Another phase III study is exploring the anti–PD-L1 therapy atezolizumab (MPDL3280A) combined with bevacizumab (NCT02420821) in comparison with sunitinib (NCT02420821).  As these therapies move into the frontline setting, it is important to understand responses, as patients appear to respond differently to an immune checkpoint inhibitor than has been seen with other therapies, says Hutson. In some situations, the tumor may grow momentarily before shrinkage is observed, in a phenomenon known as pseudoprogression, explains Hutson. While tumors do ultimately regress, it can be challenging for clinicians to distinguish pseudoprogression from true progression, adds David F. McDermott, MD, who emphasizes the importance of maintaining therapy and not discontinuing treatment too soon. 

...

 
<< Start < Prev 71 72 73 74 75 76 77 78 79 80 Next > End >>

Page 74 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.